Alzheimer Disease

26 competing products in clinical development for Alzheimer Disease.

Pipeline by Phase

Phase 14

Phase 1/21

Phase 215

Phase 2/32

Phase 34

Product	Company	Stage	Status	Hype
Donanemab + Placebo	Eli Lilly	Phase 3	Recruiting	47
Lemborexant 10 mg + Lemborexant 20mg + Placebo	Eisai	Phase 2	Recruiting	42
ONO-2020 + Placebo	Ono Pharmaceutical	Phase 2	Active	39
Donanemab + Placebo + LY3202626	Eli Lilly	Phase 2	Completed	35
donanemab	Eli Lilly	Phase 2	Completed	35
DONEPEZIL HYDROCHLORIDE	Eisai	Phase 2	Completed	35
Donepezil + Estrogen + Progesterone	Eisai	Phase 2	Completed	35
IGC-AD1-Active + IGC-AD1-Placebo	IGC Pharma	Phase 2	Recruiting	32
E2814	Eisai	Phase 1/2	Completed	32
Simufilam + Placebo	Cassava Sciences	Phase 3	Completed	30
LY3002813-IV + LY3002813-SC + Placebo-IV	Eli Lilly	Phase 1	Completed	29
LY3002813 + Placebo	Eli Lilly	Phase 1	Completed	29
KHK6640 + Placebo	Kyowa Kirin	Phase 1	Completed	29
ATH-1017 + Placebo	LeonaBio	Phase 2/3	Completed	28
E2609 + Placebo	Eisai	Phase 2	Terminated	27
Lemborexant 25 mg + Placebo	Eisai	Phase 2	Withdrawn	27
AL002 + Placebo	Alector	Phase 2	Completed	25
ATH-1017 + Placebo	LeonaBio	Phase 2	Completed	25
Placebo oral tablet + Simufilam 100 mg tablet + Simufilam 50 mg oral tablet	Cassava Sciences	Phase 2	Completed	25
Simufilam 100 mg oral tablet + Placebo	Cassava Sciences	Phase 2	Completed	25
PTI-125, 100 mg tablets	Cassava Sciences	Phase 2	Completed	25
Simufilam + Placebo	Cassava Sciences	Phase 3	Terminated	22
Simufilam	Cassava Sciences	Phase 3	Terminated	22
[18F]NAV4694	Navidea Biopharmaceuticals	Phase 2	UNKNOWN	21
ATH-1017	LeonaBio	Phase 2/3	Terminated	20
NDX-1017 + Placebo	LeonaBio	Phase 1	Completed	19